ADIL — Adial Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $7.83m
- $5.00m
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.24 | 10.9 | 19.3 | 10.9 | 6.89 |
Operating Profit | -8.24 | -10.9 | -19.3 | -10.9 | -6.89 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.59 | -10.9 | -19.5 | -10.8 | -7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.59 | -10.9 | -19.4 | -10.8 | -7 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -8.59 | -10.9 | -19.4 | -12.7 | -5.12 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.59 | -10.9 | -19.4 | -12.7 | -5.12 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -21.8 | -21.9 | -24.8 | -10.8 | -4.91 |